<DOC>
	<DOCNO>NCT01205932</DOCNO>
	<brief_summary>The objective dose-confirmatory bridging study investigate safety efficacy rivaroxaban 5 10 mg once-daily ( od ) dose prevention venous thromboembolism ( VTE ) Japanese patient undergo elective total hip replacement ( THR ) confirm extrapolability global data Japanese patient compare data overseas phase II study ( ODIXa-OD.HIP - Study 11527 ) .</brief_summary>
	<brief_title>Dose-confirmatory Bridging Study Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male female patient age 20 year Patients undergo elective THR ( first replacement applicable hip joint ) Patients ' write informed consent participation receive detailed verbal write information study specific procedure advance Planned , stag major orthopedic surgery within 3 month prior elective THR study History clinically significant active bleeding ( e.g . intracranial bleeding , gastrointestinal bleeding* ) , high bleeding risk * : within 3 month prior elective THR gastrointestinal bleeding Subjects hepatic disease associate coagulopathy lead clinically relevant bleeding risk Severe impair renal function ( CLCR calculate CockcroftGault formula : &lt; 30 mL/min ) Conditions prohibit bilateral venography ( e.g . amputation 1 leg , allergy contrast medium ) Ongoing anticoagulant therapy ( e.g . warfarin , heparins Factor Xa inhibitor study medication ) stop ( opinion investigator/sub investigator ) Subjects epidural catheter expect left longer 18 hour postoperatively Planned intermittent pneumatic compression treatment period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>venous thromboembolism</keyword>
	<keyword>prevention</keyword>
	<keyword>othopaedic surgery</keyword>
</DOC>